Fingolimod Hydrochloride and Hepatic impairment
Result of checking the interaction of drug Fingolimod Hydrochloride and disease Hepatic impairment for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Cases of liver injury with hepatocellular and/or cholestatic hepatitis have been reported with fingolimod in the postmarketing setting. Patients with preexisting liver disease may be at increased risk of developing elevated liver enzymes when taking fingolimod. It is recommended to obtain liver enzyme results before initiation of therapy. No dose adjustment is needed in patients with mild or moderate hepatic impairment. Closely monitor patients with severe hepatic impairment as this agent exposure is doubled in these patients and the risk of adverse reactions is greater. Discontinue if significant liver injury occurs.
Generic Name: fingolimod
Brand Name: Gilenya
Synonyms: Fingolimod